![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Overcoming Barriers and Achieving Optimal Implementation of Cabotegravir and Rilpivirine
Long-Acting (CAB + RPV LA): Staff Study Participant (SSP) Results From the CAB + RPV
Implementation Study in European Locations (CARISEL)
|
|
|
Laurence Slama1, María Crusells-Canales2, Julián Olalla Sierra3, Rebecca DeMoor4, Mounir Ait-Khaled5, Samia Dakhia5, Helena Van Mechelen6, Alison Hamilton7,8, Monica Hadi9, Dina Filipenko9, Fiona Brown9, Emma L. Low9, Cassidy A. Gutner10, Maggie Czarnogorski10
1Service d'immuno-infectiologie, Hôtel-Dieu, Paris, France; 2Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; 3Internal Medicine Department, Costa del Sol Hospital, Marbella, Málaga, Spain; 4GlaxoSmithKline, Collegeville, PA, United States; 5ViiV Healthcare, Brentford, United Kingdom; 6ViiV Healthcare, Wavre, Belgium; 7University of California, Los Angeles, CA, United States; 8Center for the Study of Healthcare Innovation, Implementation and Policy, VA Greater Los Angeles Healthcare System, Los Angeles, CA, United States; 9Evidera, London, United Kingdom; 10ViiV Healthcare, Research Triangle Park, NC, United States
![1027221](../images/102722/102722-2/1027221.gif)
![1027222](../images/102722/102722-2/1027222.gif)
![1027223](../images/102722/102722-2/1027223.gif)
![1027224](../images/102722/102722-2/1027224.gif)
![1027225](../images/102722/102722-2/1027225.gif)
![1027226](../images/102722/102722-2/1027226.gif)
![1027227](../images/102722/102722-2/1027227.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|